Benjamin J. Zeskind Buys 21,000 Shares of Immuneering Corporation (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) CEO Benjamin J. Zeskind purchased 21,000 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were purchased at an average cost of $2.39 per share, for a total transaction of $50,190.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,302,852 shares of the company's stock, valued at $5,503,816.28. This represents a 0.92% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Immuneering Price Performance

Immuneering stock traded down $0.21 during midday trading on Friday, reaching $2.56. The company had a trading volume of 4,703,958 shares, compared to its average volume of 2,522,900. Immuneering Corporation has a 12-month low of $1.00 and a 12-month high of $3.83. The company has a market capitalization of $92.13 million, a P/E ratio of -1.31 and a beta of 0.01. The firm's fifty day simple moving average is $1.62 and its 200-day simple moving average is $1.75.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). On average, analysts expect that Immuneering Corporation will post -1.86 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on IMRX. Oppenheimer reduced their price target on Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and issued a $9.00 price objective on shares of Immuneering in a research report on Wednesday. Mizuho upped their target price on Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, Chardan Capital reissued a "buy" rating and issued a $13.00 price target on shares of Immuneering in a research note on Wednesday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.25.

Hedge Funds Weigh In On Immuneering

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. acquired a new stake in Immuneering in the 4th quarter valued at about $390,000. First Manhattan CO. LLC. purchased a new stake in shares of Immuneering in the fourth quarter valued at approximately $71,000. Bridgeway Capital Management LLC increased its holdings in shares of Immuneering by 77.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after purchasing an additional 22,400 shares during the last quarter. Marshall Wace LLP purchased a new position in Immuneering during the fourth quarter worth approximately $47,000. Finally, XTX Topco Ltd lifted its position in Immuneering by 177.2% during the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after buying an additional 20,871 shares in the last quarter. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.